Literature DB >> 15158522

Prevalence of the metabolic syndrome in US populations.

Earl S Ford1.   

Abstract

The prevalence of the metabolic syndrome using either the National Cholesterol Education Program Adult Treatment Panel III or World Health Organization definitions is high and likely increasing among US adults. The large number of people with the metabolic syndrome has serious implications for public health and clinical practice. The associated costs are likely to be substantial. Future increases in the incidence of cardiovascular disease and diabetes could occur. Because patients with the metabolic syndrome will make up a large proportion of the practices of health care professionals, health care professionals must be knowledgeable about the metabolic syndrome and be prepared to diagnose it.

Entities:  

Mesh:

Year:  2004        PMID: 15158522     DOI: 10.1016/j.ecl.2004.03.004

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  29 in total

1.  Suboptimal inhibition of platelet cyclooxygenase-1 by aspirin in metabolic syndrome.

Authors:  James P Smith; Elias V Haddad; Mary B Taylor; Denise Oram; Dana Blakemore; Qingxia Chen; Olivier Boutaud; John A Oates
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 2.  Genetics of metabolic syndrome.

Authors:  Alena Stančáková; Markku Laakso
Journal:  Rev Endocr Metab Disord       Date:  2014-12       Impact factor: 6.514

3.  Increased 10-year cardiovascular disease and mortality risk scores in asymptomatic patients with calcium oxalate urolithiasis.

Authors:  Hasan Aydin; Faruk Yencilek; Ismet Bilger Erihan; Binnur Okan; Kemal Sarica
Journal:  Urol Res       Date:  2011-05-13

4.  Metabolic syndrome is independently associated with increased 20-year mortality in patients with stable coronary artery disease.

Authors:  Arwa Younis; Anan Younis; Boaz Tzur; Yael Peled; Nir Shlomo; Ilan Goldenberg; Enrique Z Fisman; Alexander Tenenbaum; Robert Klempfner
Journal:  Cardiovasc Diabetol       Date:  2016-10-28       Impact factor: 9.951

5.  Adiponectin and metabolic syndrome in a Tunisian population.

Authors:  Samir Ben Ali; Riadh Jemaa; Bouchra Ftouhi; Amani Kallel; Moncef Feki; Hedia Slimene; Naziha Kaabachi
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

6.  Genetic polymorphisms in carnitine palmitoyltransferase 1A gene are associated with variation in body composition and fasting lipid traits in Yup'ik Eskimos.

Authors:  Dominick J Lemas; Howard W Wiener; Diane M O'Brien; Scarlett Hopkins; Kimber L Stanhope; Peter J Havel; David B Allison; Jose R Fernandez; Hemant K Tiwari; Bert B Boyer
Journal:  J Lipid Res       Date:  2011-11-01       Impact factor: 5.922

Review 7.  The renin angiotensin aldosterone system and insulin resistance in humans.

Authors:  Patricia C Underwood; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2013-02       Impact factor: 5.369

8.  Distinct component profiles and high risk among African Americans with metabolic syndrome: the Jackson Heart Study.

Authors:  Herman Taylor; Jiankang Liu; Gregory Wilson; Sherita H Golden; Errol Crook; Claude D Brunson; Micheal Steffes; William D Johnson; Jung Hye Sung
Journal:  Diabetes Care       Date:  2008-03-10       Impact factor: 19.112

Review 9.  AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease.

Authors:  Aaron K F Wong; Jacqueline Howie; John R Petrie; Chim C Lang
Journal:  Clin Sci (Lond)       Date:  2009-04       Impact factor: 6.124

10.  Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

Authors:  Dick C Chan; Gerald F Watts; Esther M M Ooi; Kerry-Anne Rye; Juying Ji; Anthony G Johnson; P Hugh R Barrett
Journal:  Diabetes Care       Date:  2009-08-03       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.